-
31.发明申请公开(公告)号：US20210221888A1
公开(公告)日：2021-07-22
申请号：US17186960
申请日：2021-02-26
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K38/00 , A61K38/14 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K33/36 , A61K39/395 , A61K38/16 , A61K38/18 , A61K38/20 , A61K31/4155 , A61K38/02
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
32.发明申请公开(公告)号：US20210188977A1
公开(公告)日：2021-06-24
申请号：US17187011
申请日：2021-02-26
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K38/00 , A61K38/14 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K33/36 , A61K39/395 , A61K38/16 , A61K38/18 , A61K38/20 , A61K31/4155 , A61K38/02
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
33.发明授权公开(公告)号：US10995141B2
公开(公告)日：2021-05-04
申请号：US16852508
申请日：2020-04-19
Inventor： Ester Yoles , Berit Olsen Krogh , Allan Jensen , Jan Egebjerg , Carol David , Kuti Baruch , Michal Eisenbach-Schwartz
Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
-
34.发明授权公开(公告)号：US10981989B2
公开(公告)日：2021-04-20
申请号：US16284081
申请日：2019-02-25
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: A61K39/395 , C07K16/28 , A61K38/00 , A61K38/14 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K33/36 , A61K38/16 , A61K38/18 , A61K38/20 , A61K31/4155 , A61K38/02 , A61K39/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
35.发明授权公开(公告)号：US10144778B2
公开(公告)日：2018-12-04
申请号：US15125249
申请日：2015-03-12
Applicant: Yeda Research and Development Co. Ltd
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K38/00 , A61K31/4155 , A61K38/16 , A61K38/18 , A61K38/20 , A61K38/14 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K33/36 , A61K38/02 , A61K39/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
Patent Agency Ranking
36.发明授权公开(公告)号：US09982049B2
公开(公告)日：2018-05-29
申请号：US15821603
申请日：2017-11-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: A61K39/395 , C07K16/28 , A61K38/16 , A61K31/4155 , A61K45/06 , A61K38/18 , A61K38/14 , A61K38/00 , A61K33/36 , A61K31/7068 , A61K38/20 , A61K31/404 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
37.发明申请公开(公告)号：US20180111997A1
公开(公告)日：2018-04-26
申请号：US15821595
申请日：2017-11-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K45/06 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/14 , A61K38/16 , A61K38/18 , A61K31/404 , A61K39/395 , A61K38/20 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
38.发明申请公开(公告)号：US20180009893A1
公开(公告)日：2018-01-11
申请号：US15698800
申请日：2017-09-08
Applicant: Yeda Research and Development Co. Ltd
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K39/00
CPC classification number: C07K16/2827 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61P25/16 , A61P25/28 , A61P27/02 , A61P37/06 , C07K16/2803 , C07K16/2818 , C07K2317/76 , A61K2300/00
Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
39.发明申请公开(公告)号：US20170240634A1
公开(公告)日：2017-08-24
申请号：US15125249
申请日：2015-03-12
Applicant: Yeda Research and Development Co. Ltd
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K31/4155 , A61K38/02
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
40.发明授权Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease 有权减少系统性调节性T细胞水平或治疗阿尔茨海默病的活性公开(公告)号：US09512227B2
公开(公告)日：2016-12-06
申请号：US15202493
申请日：2016-07-05
Applicant: Yeda Research and Development Co. Ltd
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: A61K39/395 , C07K16/28 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
Abstract translation: 一种包含活性剂的药物组合物，其引起个体中用于治疗不包括自身免疫性神经炎症性疾病，复发性多发性硬化症（RRMS）的疾病，病症，病状或损伤的个体的全身免疫抑制水平的降低 ）。 药物组合物用于通过包含至少两个治疗疗程的剂量方案给药，每个治疗过程依次包括治疗会话，随后是间隔期。
-
-
-
-
-
-
-
-
-
Search Results
43
records
(took 0.04 seconds)
